Segall Bryant & Hamill LLC Sells 40,257 Shares of Geron Co. (NASDAQ:GERN)

Segall Bryant & Hamill LLC lessened its stake in shares of Geron Co. (NASDAQ:GERN) by 1.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,077,079 shares of the biopharmaceutical company’s stock after selling 40,257 shares during the period. Segall Bryant & Hamill LLC’s holdings in Geron were worth $18,510,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. Darwin Global Management Ltd. bought a new position in Geron in the 2nd quarter worth $106,185,000. Renaissance Technologies LLC purchased a new position in Geron in the 2nd quarter worth approximately $3,315,000. Price T Rowe Associates Inc. MD grew its holdings in Geron by 999.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock valued at $6,815,000 after buying an additional 1,877,184 shares in the last quarter. Algert Global LLC bought a new stake in Geron in the 2nd quarter valued at $539,000. Finally, Farallon Capital Management LLC lifted its stake in Geron by 124.6% in the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock worth $71,389,000 after purchasing an additional 9,342,000 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Leerink Partners initiated coverage on Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 price objective for the company. Scotiabank started coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price for the company. Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Geron in a report on Thursday, August 8th. HC Wainwright began coverage on shares of Geron in a report on Tuesday, November 5th. They issued a “buy” rating and a $8.00 price target for the company. Finally, Leerink Partnrs raised Geron to a “strong-buy” rating in a research note on Monday, September 9th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.05.

Geron Price Performance

Shares of GERN stock opened at $3.99 on Thursday. The stock has a 50 day moving average price of $4.23 and a 200 day moving average price of $4.31. Geron Co. has a 52-week low of $1.64 and a 52-week high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The firm has a market capitalization of $2.41 billion, a P/E ratio of -12.47 and a beta of 0.52.

Geron (NASDAQ:GERN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. The business had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business’s revenue for the quarter was up 17138.4% compared to the same quarter last year. During the same period last year, the company earned ($0.08) earnings per share. As a group, sell-side analysts predict that Geron Co. will post -0.25 earnings per share for the current year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.